Cartesian Therapeutics Goodwill

As of the most recent data (June 2026), RNAC shows a goodwill of $48M. That compares with $48M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RNAC's goodwill is now $48M (was $48M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Cartesian Therapeutics is outperforming or lagging.

Tracking RNAC's goodwill over time shows whether Cartesian Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $48M That compares with $48M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this goodwill page, Stockcircle has Cartesian Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect goodwill (currently $48M) with ownership activity and broader fundamentals.

Cartesian Therapeutics's goodwill is $48M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.